Table 1.
Patient characteristics.
| Total | Further-Line Patient Group | First-Line Patient Group | |
|---|---|---|---|
| n = 111 | n = 71 | ||
| Age (yrs) | median (range) | 65 (36–89) | 67 (43–82) |
| standard deviation | 9.7 | 9.3 | |
| Sex | female | 35 (31.5%) | 22 (31%) |
| male | 76 (68.5%) | 49 (69%) | |
| Smoker | yes | 100 (90.1%) | 63 (88.7%) |
| no | 11 (9.9%) | 8 (11.3%) | |
| BMI | median (range) | 24 (17.1–42.5) | 24.5 (16.2–35.2) |
| Histologic subtype | Adenocarcinoma | 84 (75.7%) | 59 (83.1%) |
| Squamous cell carcinoma | 27 (24.3%) | 12 (16.9%) | |
| Immune-rel. Adverse Events | yes | 31 (27.9%) | 24 (33.8%) |
| no | 80 (72.1%) | 47 (66.2%) | |
| Lymphocytes (G/l) | median | 1.09 (0.17–3.75) | 1.47 (0.31–4.7) |
| standard deviation | 0.7183 | 0.7579 | |
| Normal range (1.5–4) | 34 (30.6%) | 34 (47.9%) | |
| Not in normal range | 77 (69.4%) | 37 (52.1%) | |
| Monocytes (G/l) | median | 0.81 (0.09–1.98) | 0.69 (0.02–3.1) |
| standard deviation | 0.3308 | 0.4058 | |
| Normal range (0.16–0.95) | 80 (72.1%) | 54 (76.1%) | |
| Not in normal range | 31 (27.9%) | 17 (23.9%) | |
| Neutrophils (G/l) | median | 4.76 (0.3–13.89) | 5.1 (1.25–16.7) |
| standard deviation | 2.598 | 2.7834 | |
| normal range (1.4–8) | 95 (85.6%) | 58 (81.7%) | |
| Not in normal range | 16 (14.14%) | 13 (18.3%) | |
| Eosinophils (G/l) | median | 0.12 (0–1.09) | 0.16 (0.01–0.5) |
| standard deviation | 0.2069 | 0.1295 | |
| Normal range (0–0.7) | 107 (96.4%) | 71 (100%) | |
| Not in normal range | 4 (3.6%) | 0 (0%) | |
| Basophils (G/l) | median | 0.02 (0.01–0.1) | 0.04 (0.01–0.12) |
| standard deviation | 0.0217 | 0.0223 | |
| Normal range (0–0.15) | 111 (100%) | 71 (100%) | |
| Not in normal range | 0 (0%) | 0 (0%) | |
| PDL1-TC | <1% | 45 (40.5%) | 23 (32.4%) |
| 1–50% | 33 (29.8%) | 28 (39.4%) | |
| >50% | 15 (13.5%) | 19 (26.8%) | |
| not available | 18 (16.2%) | 1 (1.4%) | |
| Response (CR, PR) at 3 months | yes | 36 (32.4%) | 36 (50.7%) |
| no | 75 (67.6%) | 35 (49.3%) | |
| Antibiotics | yes | 55 (49.5%) | 42 (59.2%) |
| no | 56 (50.5%) | 29 (40.8%) | |
| NSAR | yes | 42 (37.8%) | 20 (28.2%) |
| no | 69 (62.2%) | 51 (71.8%) | |
| Steroids | yes | 52 (46.8%) | 43 (60.6%) |
| no | 59 (53.2%) | 28 (39.4%) | |
| Metformin | yes | 9 (8.1%) | 4 (5.6%) |
| no | 102 (91.9%) | 67 (94.4%) | |
| Treatment | ICI & Chemo | 11 (9.9%) | 42 (59.2%) |
| ICI | 100 (90.1%) | 29 (40.8%) | |
| OS (days) | median (range) | 340 (9–1807) | 461 (61–1198) |
| standard deviation | 463.3 | 290.2 |
OS: overall survival is calculated from the day of start of treatment to death (or censored); NSAR: non-steroidal anti-rheumatic drug; CR: complete response; PR: partial response; SD: stable disease; PD: progressing disease; BMI: body mass index; PD-L1TC: PD-L1 expression in tumor cells.